Oleanolic Acid Glucoside for Ulcerative Colitis Barrier Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug therapies for ulcerative colitis, such as aminosalicylates and glucocorticoids, fail to effectively alleviate symptoms and are associated with severe side effects, and there is a lack of evidence on the anti-ulcerative-colitis effects of oleanolic acid-28-O-β-D-glucopyranoside.
Innovation Solution
The use of oleanolic acid-28-O-β-D-glucopyranoside in the preparation of a drug to reduce levels of TNF-α, IL-6, iNOS, MPO, and MDA, and increase SOD levels, while improving colon length and reducing intestinal permeability and disease activity index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drug therapies (aminosalicylates, glucocorticoids) are used for ulcerative colitis treatment, then anti-inflammatory effect is achieved, but severe side effects occur and symptoms are not effectively alleviated
Solution Approach 1:
The patent extracts and isolates the active anti-inflammatory component (oleanolic acid-28-O-β-D-glucopyranoside) from traditional Chinese medicine formulations, separating the beneficial therapeutic effect from the harmful side effects associated with conventional drugs like aminosalicylates and glucocorticoids
Solution Approach 2:
The patent introduces oleanolic acid-28-O-β-D-glucopyranoside as an intermediary substance that mediates the anti-inflammatory effect, providing an alternative pathway that achieves therapeutic benefits without the severe side effects of current standard treatments
2Duration of action of stationary object
If current drug therapies are used for long-term treatment, then sustained anti-inflammatory effect is maintained, but severe side effects accumulate
Solution Approach 1:
The patent employs oleanolic acid-28-O-β-D-glucopyranoside as a short-acting but potent anti-inflammatory agent that can be administered repeatedly without cumulative toxicity, replacing long-acting drugs with severe accumulated side effects
3Reliability
If traditional Chinese medicine formulations are used, then anti-inflammatory activity is achieved, but lack of evidence on specific anti-ulcerative-colitis effects exists
Solution Approach 1:
The patent segments the complex traditional Chinese medicine formulation into a specific active component (oleanolic acid-28-O-β-D-glucopyranoside), enabling targeted investigation and generation of evidence for anti-ulcerative-colitis effects while maintaining the beneficial anti-inflammatory properties
Data Source
AI summary
A use of oleanolic acid-28-O-β-D-glucopyranoside in the preparation of an anti-colitis drug is provided. The oleanolic acid-28-O-β-D-glucopyranoside has significant anti-ulcerative-colitis activity compared with parent nucleus oleanolic acid and other analogues, and has equivalent efficacy compared with Mesalazine, a first-line drug for the clinical treatment of inflammatory bowel disease, and can also avoid salicylic acid anaphylaxis possibly caused by Mesalazine western medicine treatment, thereby achieving a good application prospect.